Trinity biotech announces the successful closing of the $30 million sale of its life sciences supply business to biosynth

Dublin, ireland, april 27, 2023 (globe newswire) -- trinity biotech plc (nasdaq: trib) (the “company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today announced that it has closed the recently announced sale of its fitzgerald industries life sciences supply business, consisting of benen trading ltd and fitzgerald industries international, inc, to biosynth for cash proceeds of approximately $30 million subject to customary adjustments. biosynth is owned, amongst others, by kkr, ampersand capital partners and management.
TRIB Ratings Summary
TRIB Quant Ranking